US2008095832A1PendingUtilityA1

Prosaposin as a neurotrophic factor

71
Assignee: O'BRIEN JOHN SPriority: Jul 30, 1993Filed: Apr 16, 2007Published: Apr 24, 2008
Est. expiryJul 30, 2013(expired)· nominal 20-yr term from priority
Inventors:John S. O'BrienYasuo Kishimoto
A61K 9/127C07K 14/47C07K 14/705C07K 14/715C07K 7/06A61K 9/0051C07K 14/71A61K 9/0085A61P 25/28A61K 38/00A61K 9/0019C07K 7/08E03B 7/074A61K 9/19A61P 25/00C07K 14/52C07K 14/475A61P 25/16A61K 9/0048Y02A50/30
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large, neurons of the brain, including both upper and lower motor neurons.

Claims

exact text as granted — not AI-modified
1 - 42 . (canceled)  
     
     
         43 . A neurotrophic peptide consisting of amino acids 18-22 (Leu-Ile-Asp-Asn-Asn) of SEQ ID NO:3.  
     
     
         44 . A composition comprising the neurotrophic peptide of  claim 43  and a pharmaceutically acceptable carrier.  
     
     
         45 . A composition comprising the neurotrophic peptide of  claim 43 , formulated with a controlled release material.  
     
     
         46 . A composition comprising the neurotrophic peptide of  claim 43 , formulated in lyophilized form.  
     
     
         47 . A composition comprising the neurotrophic peptide of  claim 43 , in liposomal form.  
     
     
         48 . A composition comprising the neurotrophic peptide of  claim 43 , in a form suitable for topical administration.  
     
     
         49 . A composition comprising the neurotrophic peptide of  claim 43 , formulated in unit dosage form.  
     
     
         50 . A composition comprising the neurotrophic peptide of  claim 43 , formulated in a septum sealed vial.  
     
     
         51 - 67 . (canceled)  
     
     
         68 . A substantially pure polypeptide consisting of the sequence: Tyr-Lys-Glu-Val-Thr-Lys-Leu-Ile-Asp-Asn-Asn-Lys-Thr-Glu-Lys-Glu-Ile-Leu (SEQ ID NO:5).  
     
     
         69 . A pharmaceutical composition comprising a neurotrophic polypeptide consisting of amino acids of SEQ ID NO:5 and a pharmaceutically acceptable carrier.  
     
     
         70 . The pharmaceutical composition of  claim 69  which is formulated for containment in a septum sealed vial.  
     
     
         71 . The pharmaceutical composition of  claim 69  which is formulated with a controlled release material.  
     
     
         72 . The pharmaceutical composition of  claim 69  which is formulated in a liposomal form.  
     
     
         73 - 95 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.